undamentalytics Newsletter
Sign in

Biostem Technologies, Inc. (BSEM) stock

Add to watchlist

Add holding +

NASDAQ: BSEM Nasdaq Biotechnology Next results ~November 12, 2026

Biostem Technologies, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.

Biostem Technologies, Inc. valuation: adjust assumptions and compare models →

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Biostem Technologies, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 122% and a beta of 1.4 against the S&P 500.

Latest results

Earnings per share
-$0.52 against an average estimate of -$0.50: missed by 4.0%
Share reaction
-14.1% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026

Biostem Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.6%
  • 1 week-24.7%
  • 1 month-57.5%
  • This year-69.6%
  • 1 year-76.1%
  • 5 years-19.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement
  3. Results
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biostem Technologies, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Biostem Technologies, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12%: the 10-year Treasury yield (4.9%) plus a beta of 1.57 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biostem Technologies, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $7m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.90 −387% $29m —
Next −$1.04 +45% $54m +88%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.6% on 90 days ago. In the last 30 days, 1 analyst raised Biostem Technologies, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Biostem Technologies, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.95 Current fiscal year, 60 days ago: −$1.95 Current fiscal year, 30 days ago: −$1.95 Current fiscal year, 7 days ago: −$1.95 Current fiscal year, Now: −$1.90 −$1.90 Next fiscal year, 90 days ago: −$0.31 Next fiscal year, 60 days ago: −$0.31 Next fiscal year, 30 days ago: −$0.31 Next fiscal year, 7 days ago: −$0.31 Next fiscal year, Now: −$1.04 −$1.04

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.95−$0.31
60 days ago −$1.95−$0.31
30 days ago −$1.95−$0.31
7 days ago −$1.95−$0.31
Now −$1.90−$1.04

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.50 −$0.52 −4.0%
Mar 2026 −$0.28 −$0.52 −85.7%
Sept 2025 $0.00 $0.06 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Biostem Technologies, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
—
of tradable shares
Days to cover
2
at average volume
Short interest, 1 month
+149%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
31.4%
of shares
Employees
73
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BSEM−28%+188%+96%+136%−73%−70%
Industry peers (median)−36%−57%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BSEM25%67%50%50%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BSEM−52%−38%−67%−55%−82%−86%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 98% from December 7, 2015 to July 30, 2020. Getting back needed a 3871% gain, reached on November 4, 2024, 1558 days after the low.

Price behaviour

52-week range
$1.12 – $8.20
From 52-week high
−85.9%
vs 50-day average
−61.8%
vs 200-day average
−72.2%
Volatility (1 year)
122%
Beta vs S&P 500
1.38

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 1 down
typical move ±14.1%
After a week
0 up, 1 down
typical move ±7.3%
After a month
1 up, 0 down
typical move ±19.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −14.1% +0.9% −7.3% +19.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial health

5 of 6 checks passed · June 30, 2026
What it owns · $49m
Short-term assets $21mLonger-term assets $28m
What it owes, and who funded it · $49m
Short-term liabilities $21mLonger-term liabilities $0mShareholders' equity $28m
  • Short-term assets cover short-term liabilities $21m of assets due within a year against $21m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $21m short-term assets against $1,355 of longer-dated liabilities.
  • More cash than debt $7m of cash against $0 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt No debt to cover.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Biostem Technologies, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 12, 2026

Recent SEC filings

Data status

When each part of this page on Biostem Technologies, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biostem Technologies, Inc. in brief

What does Biostem Technologies, Inc. do?
Biostem Technologies, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Biostem Technologies, Inc.'s stock ticker?
Biostem Technologies, Inc. trades under the ticker BSEM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
How much debt does Biostem Technologies, Inc. have?
Biostem Technologies, Inc.'s debt-to-equity ratio is 0.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
When is Biostem Technologies, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biostem Technologies, Inc. announces its own schedule.